supply of coronary drug eluting stents,srph153049-coronary drug eluting stents (1) single wire technology on c obalt based alloy platform (2) stent with coating of biolinx polymer carrier for ac tive drug zotarolimus shown to be effective in preventing neo-intimal hyperplasia) (3) stent diameter should be from 2.25 mm to 4 mm and length of the stent from 12mm to 38 mm. (4) the strut thickness should be 81 micron or less. (5) stent delivery syste m should be monorail (single operator exchange or rapid exchange). (6) stent shou ld be compatible with 5fr guiding catheter (7) stent design should be open cell type . (8) stent should be approved by dcgi. the copy of dcgi approval should be enclose d in the tender bid. (9) five years long term efficacy and safety of the stent in term s of target vessel revascularisation (tvr) and in-situ thrombosis (ist) should be do cumented / published in peer reviewed scientific journals.(10) the documents pertai ning to the efficacy and safety of the stent should be enclosed for the brand that is offered in the tender bid (11) the manufacturer/supplier should submit proof of supply of the stent to a major government institute. unit:no